HISTONE DEACETYLASE INHIBITOR
Istodax is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat cutaneous T-cell lymphoma and peripheral T-cell lymphoma (PTCL). Istodax is indicated in cases where at least one previous therapy has failed. Istodax is also referred to by its drug name, romidepsin.
Istodax is an anticancer drug. Istodax is a member of a class of drugs called histone deacetylase inhibitors. Istodax is believed to work by killing cancer cells and slowing their growth.
How do I take it?
Istodax is administered by intravenous injection on three specific days of a 28-day cycle.
Istodax comes in the form of a single-dose vial.
The FDA-approved label for Istodax lists common side effects including fatigue, infections, nausea, loss of appetite, and low blood cell counts.
Rare but serious side effects listed for Istodax include dangerously low blood cell count, potentially life-threatening infections, cardiac abnormalities, fetal harm, and tumor lysis syndrome (a potentially fatal metabolic condition caused when many cancer cells die at the same time).
For more details about this treatment, visit:
Istodax — Chemocare
Targeted Therapy Drugs for Non-Hodgkin Lymphoma — American Cancer Society